Tower Research Capital LLC (Trc) Nrx Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.29 - $0.7 $501 - $1,211	1,730 Added 8.78%	21,426 $10,000
Q4 2023 Feb 13, 2024	BUY	$0.26 - $0.47 $2,733 - $4,942	10,515 Added 114.53%	19,696 $9,000
Q3 2023 Nov 14, 2023	SELL	$0.23 - $0.5 $4,313 - $9,377	-18,755 Reduced 67.14%	9,181 $2,000
Q2 2023 Aug 14, 2023	BUY	$0.46 - $0.89 $6,023 - $11,653	13,094 Added 88.22%	27,936 $13,000
Q1 2023 May 09, 2023	BUY	$0.66 - $1.4 $5,768 - $12,236	8,740 Added 143.23%	14,842 $10,000
Q4 2022 Feb 10, 2023	SELL	$0.79 - $9.19 $5,398 - $62,804	-6,834 Reduced 52.83%	6,102 $7,000
Q3 2022 Nov 10, 2022	BUY	$0.2 - $8.07 $1,776 - $71,685	8,883 Added 219.17%	12,936 $10,000
Q2 2022 Aug 15, 2022	SELL	$0.51 - $2.42 $551 - $2,616	-1,081 Reduced 21.06%	4,053 $2,000
Q1 2022 May 12, 2022	BUY	$2.45 - $5.04 $12,041 - $24,771	4,915 Added 2244.29%	5,134 $13,000
Q4 2021 Feb 14, 2022	SELL	$4.5 - $11.91 $3,631 - $9,611	-807 Reduced 78.65%	219 $1,000
Q3 2021 Nov 15, 2021	BUY	$8.52 - $24.77 $7,625 - $22,169	895 Added 683.21%	1,026 $10,000
Q2 2021 Aug 16, 2021	BUY	$11.62 - $44.5 $1,522 - $5,829	131 New	131 $1,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $101M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.